lorcaserin (belviq) Report issue

Small molecule Approved FDA First in Class
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

(1r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine | 8-chloro-2,3,4,5-tetrahydro-1-methyl-1h-3-benzazepine | apd356 | apd 356 | apd-356 | ar-10a | belviq | lorcaserin | lorcaserin hcl | lorcaserin hydrochloride | lorcaserin hydrochloride hemihydrate | lorqess

Organizations (32)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (1)


 

Obesity (approved 2012)

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Alcoholism (Phase 2)

Analgesics, Opioid (Phase 1)

Body Weight (Phase 4)

Breast Neoplasms (Phase 1)

Cannabis (Phase 1/Phase 2)

Cardiovascular Diseases (Phase 4)

Cocaine-Related Disorders (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Digestive System Neoplasms (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Epilepsies, Myoclonic (Phase 3)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Muscle Weakness (Phase 1/Phase 2)

Obesity ()

Opioid-Related Disorders (Phase 2/Phase 3)

Overweight (Phase 4)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Sepsis (Phase 1/Phase 2)

Smoking Cessation (Phase 2/Phase 3)

Substance-Related Disorders (Phase 1)

Tobacco Smoking (Phase 2)

Tobacco Use Disorder (Phase 2)

Weight Gain (Phase 4)

Weight Loss (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue